Good health is vital to all of us, and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. That's why we at Pfizer are committed to applying science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe, effective and affordable medicines and related health care services to the people who need them.
We have a leading portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and we have an industry-leading pipeline of promising new products that have the potential to challenge some of the most feared diseases of our time, like Alzheimer's disease and cancer.
To ensure we can continue to deliver on our commitments to the patients, customers and shareholders who rely on us, we are focused on improving the way we do business; on operating with transparency in everything we do; and on listening to the views of all of the people involved in health care decisions. Through working in partnership with everyone from patients to health care providers and managed care organizations to world governments and non-governmental organizations, our goal is to ensure that people everywhere have access to innovative treatments and quality health care.
Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people suffering from brain diseases. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at diseases such as depression and anxiety, psychotic disorders, epilepsy and Huntington’s, Alzheimer’s and Parkinson’s diseases.
Dexcel Pharma is Israel’s largest private pharmaceutical
company. Founded in 1968, we develop, manufacture
and market value-added branded and generic
pharmaceuticals. With a diverse product portfolio that
spans more than 55 branded and generic products in
over 140 dosage forms, our products are sold in the US,
the UK and Germany, via subsidiaries and through a
trusted network of partners in more than 30 countries worldwide.
Track Record of Market innovation and Success
History of successful development and commercialization of novel drug formulations utilizing Dexcel’s proprietary drug delivery technologies. Dexcel’s Omeprazole Delayed-Release Tablet – a Proton Pump Inhibitor – is the bestselling Over-The-Counter product in the US heartburn market category.
Sophisticated R&D
Dexcel’s R&D approach applies creative thinking across multiple dimensions to bring innovation to address patient unmet needs. Dexcel’s philosophy calls for imagination in drug formulation, sophisticated regulatory strategy, and careful product selection.
State-of-the-art Manufacturing
Fully automated manufacturing facilities for oral solid dose forms are located in the central Israel city of Or Akiva, alongside corporate headquarters and R&D. Additional research and manufacturing facilities are located in Yokneam and Jerusalem.
Dexcel Worldwide
We are committed to long-term growth, entering new markets and constantly enhancing our product line. Operating throughout the world makes us more responsive, helps us to identify opportunities and understand the challenges in the markets where our products are sold. Today, approximately 80% of our revenues are generated outside of Israel, making Dexcel a truly global enterprise.
Sam-On (Meditec) is a family owned pharmaceutical manufacturer engaged and specialized in development, production, distribution and marketing of pharmaceuticals (Rx and OTC), special nutritional supplements and medical devices.
Sam-On (Meditec) is a fully integrated company possessing active R&D
manufacturing, registration and regulatory affairs, marketing, sales and nationwide
distribution capabilities, in house.
Our products are market leaders in their therapeutic categories and have driven growth of the company every year.
Sam-On (Meditec)'s diverse line (over 50 finished registered products) consists of branded OTCs, branded ethicals, branded food supplements, generics and medical devices.
Sam-On (Meditec) specializes in developing and manufacturing OTC drugs containing unique formulations/combinations with an added medical value (including natural or herbal ingredients).
Sam-On (Meditec)'s portfolio includes broad therapeutic categories such as cardiovascular, gastroenterology, gynecology and women's health, respiratory, diabetes and CNS disorders.
Our products are market leaders in their therapeutic categories and have driven growth of the company every year.
Sam-On (Meditec) is committed to maintain high quality production standards.
Sam-On (Meditec) operates in accordance with the Israeli Ministry of Health's GMP standards and maintains an ongoing quality control system throughout all of the development and production processes.
Facilities are ISO 9001 & GMP & ISO 13485 approved.
Sanofi, a global life sciences company
Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. More than 110,000 people at Sanofi are dedicated to make a difference on patients’ daily life, wherever they live and enable them to enjoy a healthier life.
At Sanofi, we have a clear and resolute line for action: to contribute to the continuous advancement of health. As a company, and as individuals, Sanofi and its talented employees have always striven to advance the cause of health by developing treatments that prevent and treat diseases, while enhancing access to healthcare for the people around the world.
The expertise we have developed along the way has had a profound effect, particularly in the developing world. We have developed the first vaccine for the dengue virus, which infects 390 million people each year, and whose range is expanding due to climate change. Since the beginning of the year, first vaccinations campaigns have started in the Philippines. Thanks to systematic vaccination campaigns, we are close to eradicating polio; while over the last decade, sleeping sickness treatments have saved more than 180,000 lives. In addition, we provide innovative treatments for global killers like diabetes and cardiovascular diseases.
Finally, our commitment to health goes beyond medicine, in part through our corporate responsibility approach and our dedication to make a real difference in the lives of people every day.
Teva is committed to increasing access to high-quality healthcare for people across the globe, at every stage of life. We do this by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients.
The company’s line of generic and specialty treatments is backed by our impressive global development and manufacturing capabilities, ensuring the highest quality and accessibility to medicines while reducing costs. Teva’s participation in a wide range of therapeutic areas and dosage forms is empowered by a unique integration of innovative specialty and generic research.
Some Facts and Figures
Teva was established in 1901. Our global headquarters are based in Israel.
Today we have a portfolio of more than 1,000 molecules, producing approximately 64 billion tablets and capsules a year at 66 manufacturing facilities.
We rank among the 10 top pharmaceutical companies in the world and are active in 60 countries. Approximately 58,000 employees around the world are dedicated to our mission.
We attribute our success to:
A Corporate Culture of Caring
Teva employees know their efforts go beyond achieving business results, and that Teva strives to create a work environment that enriches both their professional and personal lives through:
Areas of Focus
Specialty Medicines:
Turning insights into Treatments
Teva's scientific and commercial expertise has propelled us to a leading position in specialty pharmaceuticals. Our specialty medicines business is focused on delivering innovative solutions to patients and providers via medicines, devices and services in all key regions and markets around the world, and includes the core therapeutic areas of CNS disorders and respiratory illnesses. We also have specialty products in oncology, women’s health and other areas.
Generic Medicines
Making Healthcare More Accessible to All
We help patients in a way that few other companies can. Our generic medicines meet critical consumer and societal needs through:
OTC Products
Promoting Consumer Self-care and Well-being
Teva has an important and growing global OTC business. PGT Healthcare, our winning alliance with The Procter & Gamble Company, combines our production capabilities and market reach with Procter & Gamble’s marketing expertise and expansive global platform.
Active Pharmaceutical Ingredients (API)
A Trusted Global API Supplier
Teva is the leading global supplier of active pharmaceutical ingredients (APIs), the essential raw materials of the drug manufacturing industry.
Unipharm was founded in 1975 in Israel and since its early days was a dominant player in the pharmaceutical arena in Israel.
Unipharm is dedicated to the manufacture of generic pharmaceutical products of high quality, capable of competing on an equal footing with major international market leaders. Unipharm's products are sold under their brand-names and are therefore classified as branded generics.
Most of Unipharm's product line is manufactured under contract by Trima Ltd. a company with which Unipharm has had a close and fruitful relationship for many years, to the mutual benefit of both parties.
Although the product line marketed by Unipharm is extensive in scope, encompassing many therapeutic areas, the company has developed a strong commitment to the fields of cardiovascular medicine, neurology/psychiatry, gastroenterology, ophthalmic and antibiotics.
One of Unipharm's main skills is developing and registering the generic's dossier as quick as possible, and therefore becoming in many cases the first generic entrant to the market. By doing that Unipharm was able to capture high market shares and lower the drug cost to health-customers. Many of Unipharm's new-product launches have made extensive change on patients' lives due to lower cost of drug-treatments and eased restrictions made by HMOs.
This enables Unipharm to collaborate with international generic player in exchange of knowledge in order to launch premium generics outside of Israel.
Another dominant feature is Unipharm's involvement in intellectual property activities. In the current pharmaceutical-IP environment where major pharmaceutical companies are protecting their product with multiple patents, Unipharm has the capabilities of accurately evaluating a product's patent protection suit and to act accordingly: either to stay off the market until the patents expire, to try to go around the still valid patents or to try to invalidate the patent and launch a generic version as soon as legally possible.
Besides the day to day manufacture of pharmaceuticals, Unipharm is also involved in the origination and initiation of pharmaceutical and pharmacological research, most of which is conducted in collaboration with Israeli institutes of higher education. The work focuses on the synthesis of pharmaceutical fine chemicals and the development of analytical methods that go beyond the scope of standard monographs, in order to ensure that the company's products are always of premium quality.
This constant striving for top quality, directly contributes to the high esteem in which Unipharm's products are held, despite fierce market competition.
